GlobeNewswire: BrainsWay Ltd. Contains the last 10 of 227 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T02:06:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2853941/0/en/BrainsWay-Announces-Positive-Results-in-Late-Life-Depression-Post-Marketing-Analysis.html?f=22&fvtc=4&fvtv=13536BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis2024-03-28T12:00:00Z<![CDATA[Data Published in Leading Peer-Reviewed Publication, Journal of Clinical Medicine Data Published in Leading Peer-Reviewed Publication, Journal of Clinical Medicine]]>https://www.globenewswire.com/news-release/2024/03/18/2847695/0/en/BrainsWay-Broadens-Partnership-with-Katie-s-Way-Plus-Through-Order-of-an-Additional-18-Deep-TMS-Systems.html?f=22&fvtc=4&fvtv=13536BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems2024-03-18T11:30:00Z<![CDATA[Katie’s Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families Katie’s Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families]]>https://www.globenewswire.com/news-release/2024/03/06/2841288/0/en/BrainsWay-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Operational-Highlights.html?f=22&fvtc=4&fvtv=13536BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights2024-03-06T12:30:00Z<![CDATA[Generated Record Revenues with Robust 50% Year-over-Year Revenue Growth in Q4 2023; Generated Positive Quarterly Net Income]]>https://www.globenewswire.com/news-release/2024/02/21/2832693/0/en/BrainsWay-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-6-2024.html?f=22&fvtc=4&fvtv=13536BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 20242024-02-21T13:00:00Z<![CDATA[BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2023 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, March 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.]]>https://www.globenewswire.com/news-release/2024/01/10/2807001/0/en/BrainsWay-Initiates-Clinical-Evaluation-of-Rotational-Field-Deep-TMS-360-Technology.html?f=22&fvtc=4&fvtv=13536BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology2024-01-10T12:30:00Z<![CDATA[BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will be clinically evaluating an innovative stimulation technology in two new feasibility trials.]]>https://www.globenewswire.com/news-release/2023/12/19/2798441/0/en/BrainsWay-Highlights-Expanded-Deep-TMS-Access-with-Growing-Western-U-S-Network.html?f=22&fvtc=4&fvtv=13536BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network2023-12-19T12:30:00Z<![CDATA[BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced increased collaboration with a growing mental health treatment provider based in the Western region of the United States. After a series of successive orders, BrainsWay’s most recent delivery will bring this provider’s installed base to a total of seven Deep Transcranial Magnetic Stimulation (Deep TMS™) systems, with plans for additional expansion in the future.]]>https://www.globenewswire.com/news-release/2023/12/07/2792438/0/en/BrainsWay-Announces-Continued-Expansion-of-Deep-TMS-in-South-Korea.html?f=22&fvtc=4&fvtv=13536BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea2023-12-07T13:00:00Z<![CDATA[BURLINGTON, Mass. and JERUSALEM, Dec. 07, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in South Korea. After growing momentum over the past few years, recent sales are expected to bring BrainsWay’s installed base in the country to over 20 Deep TMS systems.]]>https://www.globenewswire.com/news-release/2023/11/20/2783144/0/en/Louisiana-Insurer-Expands-Deep-TMS-Access-for-1-9-Million-Covered-Lives.html?f=22&fvtc=4&fvtv=13536Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives 2023-11-20T12:30:00Z<![CDATA[BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Blue Cross Blue Shield of Louisiana (BCBS of LA) has joined the growing list of payors reducing the patient eligibility requirements for transcranial magnetic stimulation (TMS) treatment from four failed medication trials to two.]]>https://www.globenewswire.com/news-release/2023/11/15/2780920/0/en/BrainsWay-Reports-Third-Quarter-2023-Financial-Results-and-Operational-Highlights.html?f=22&fvtc=4&fvtv=13536BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights2023-11-15T12:30:00Z<![CDATA[Generated Robust 61% Year-over-Year Revenue Growth in Q3 2023]]>https://www.globenewswire.com/news-release/2023/11/02/2772233/0/en/Clinical-TMS-Society-Publishes-First-Coverage-Recommendations-for-the-Treatment-of-Smoking-Addiction.html?f=22&fvtc=4&fvtv=13536Clinical TMS Society Publishes First Coverage Recommendations for the Treatment of Smoking Addiction2023-11-02T12:00:00Z<![CDATA[BrainsWay Deep TMS™ is the Only TMS System FDA-Cleared to Treat Smoking Addiction BrainsWay Deep TMS™ is the Only TMS System FDA-Cleared to Treat Smoking Addiction]]>